Artificial intelligence (AI) in clinical trials: Implications for evidence synthesis and market access

Pharma Market Access Insights - from Mtech Access

How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?
In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of ophthalmology. George and Calum explore:
- How, when and where AI is being used in clinical trials
- How Lexitas are using AI in clinical trials for ophthalmology
- Where AI may offer solutions to existing obstacles in clinical trials and ophthalmic drug development
- What the future holds for AI in the development of new medicines
- The role AI can play in selecting patients for clinical trials
- The impact AI may have on the way we evaluate drug effectiveness
- What this all means for evidence synthesis, health economics, reimbursement and market access
- The future prospects of AI in pharmaceutical development
Learn more at: https://mtechaccess.co.uk/ai-clinical-trials-evidence/
This episode was first broadcast as a live webinar in August 2023.

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Kapitel

1. Introductions and background (00:00:00)

2. Applications of AI when creating new medicines / medical devices (00:07:06)

3. AI in patient selection for clinical trials (00:13:15)

4. Time-saving implications of using AI (00:18:50)

5. Risks or potential challenges of using AI in clinical trials (00:21:45)

6. How to assess potential biases when using AI (00:25:57)

7. Regulating the use of AI-informed efficacy in effectiveness estimates (00:29:03)

8. Impact of AI on evidence synthesis (00:31:13)

9. Using AI to devise the right set of next questions (00:35:05)

10. AI and health economics (00:36:08)

11. Future prospects of AI in pharmaceutical development (00:38:14)